Aurion Biotech
Blood & Organ Banks · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
701 Pike St Ste 2225, Seattle, Washingto...Phone Number
(206) 701-5840Website
www.aurionbiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 6
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
5
4
7
7
6
About Aurion Biotech
Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells manufactured from a single donor can treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and central corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S.Explore more
Aurion Biotech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aurion Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Aurion Biotech has recently received funding, and reach out quickly before it becomes old news!
Check out if Aurion Biotech is spiking on competitors!
Product Launch: Get notified when Aurion Biotech launches new products
Click to see if Aurion Biotech had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Aurion Biotech has new funding data
Earning: See what the market has to say on Aurion Biotech recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Aurion Biotech
Website visits: Recent activity has been detected on your website
Aurion Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Aurion Biotech
Find more new buyers
Compare Similar Companies to Aurion Biotech
Compare insights from companies similar to Aurion Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aurion Biotech is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Aurion Biotech is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Aurion Biotech.
Aurion Biotech financials insights
Gather financial insights about Aurion Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$120M
Aurion Biotech Tech Stack
A closer look at the technologies used by Aurion Biotech
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Aurion Biotech News & Media
Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments of Edward J. Holland, M.D., as Chief Medical Officer, and Eris P. Jordan, O.D., as Chief Development Officer. Aurion Biotech is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial diseaseTech Moves: Gennev founder steps down; Aurion Biotech CEO is out; Temporal adds president
— Jill Angelo, founder and CEO of Seattle menopause startup Gennev, announced that her chapter with the business is ending. Florida-based women’s health company Unified Women’s Healthcare acquired Gennev in 2022 for an undisclosed sum, and Angelo transitioned to president of virtual health at Unified. She is now resigning from that role. The acquisition “was not just a milestone — it was validation of a vision that started with a small but mighty team determinedAlcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial DiseaseAlcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Aurion Biotech
Sign Up For FreeTo access detailed company insights
Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies fo... Read More
